Market Overview:
The global liraglutide drugs market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of type 2 diabetes and obesity, rising awareness about the benefits of liraglutide drugs, and increasing R&D investments by pharmaceutical companies. The global liraglutide drugs market is segmented on the basis of type, application, and region. On the basis of type, it is divided into Victoza and Saxenda. On the basis of application, it is classified into type 2 diabetes and obesity. Geographically, it is analyzed across North America (U.S., Canada), Latin America (Mexico), Europe (Germany, U.K., France), Asia Pacific (China Japan India) Middle East & Africa(South Africa).
Product Definition:
Liraglutide Drugs is a glucagon-like peptide 1 (GLP-1) receptor agonist used to treat type 2 diabetes. It is usually used in combination with metformin and/or a sulfonylurea. Liraglutide helps the body make more insulin and decreases the amount of sugar made by the liver.
Victoza:
Liraglutide is a type of GLP-1 receptor agonist. It works by decreasing the amount of glucose in the body and increases insulin sensitivity, which helps to lower blood sugar levels. Liraglutide is used as an anti-diabetic drug and it helps to reduce HbA1C level by 0.5% every month for all patients who are on treatment with Victoza (exenatide).
Saxenda:
Saxenda is a once-weekly injectable diabetes drug that works by helping the body to produce insulin. It was approved by the FDA in 2013 and is manufactured by Novo Nordisk A/S, a Denmark-based company. The product’s main ingredient is liraglutide (brand name: Xeloda), which was developed as an anti-obesity medication but has been found to have efficacy in treating type 2 diabetes as well.
Application Insights:
The application segment is segregated into type 2 diabetes, obesity and other applications. In 2017, the type 2 diabetes segment dominated the global liraglutide drugs market owing to a high prevalence of this disease. Type 2 diabetes mellitus is also known as adult-onset or maturity-onset diabetes because it usually occurs in people aged 40 years and above.
In 2015, World Health Organization (WHO) estimated that approximately 1.5 billion people were suffering from some form of diabetic condition which required medical attention and medication.
Regional Analysis:
North America dominated the global liraglutide drugs market in 2017. The region is expected to maintain its position during the forecast period owing to favorable reimbursement policies, increasing awareness about lifestyle modification and availability of effective treatment for diabetes. In addition, rising obesity levels are also anticipated to boost product demand in this region.
Asia Pacific is expected to witness lucrative growth over the forecast period due to an increase in diabetic population and growing healthcare expenditure by governments as well as private sectors across countries such as China & India & Japan etc., which will lead towards a rise in drug sales over the next eight years.
Growth Factors:
- Increasing prevalence of obesity and diabetes: The increasing prevalence of obesity and diabetes is the major growth driver for the Liraglutide Drugs market. According to a study by the World Health Organization (WHO), in 2016, there were more than 1.9 billion adults aged 18 years or older who were overweight, and 650 million adults who were obese. Furthermore, 422 million people had diabetes worldwide in 2014, and this number is expected to increase to 629 million by 2040. This growing incidence of obesity and diabetes will lead to an increased demand for Liraglutide Drugs products, thereby driving the market growth.
- Rising awareness about weight loss therapies: There is a growing awareness among people about weight loss therapies such as Liraglutide Drugs products owing to their benefits such as improved metabolic health, weight loss, reduced risk of heart disease etc. This is resulting in an increased demand for these drugs which is propelling the market growth further.
Scope Of The Report
Report Attributes
Report Details
Report Title
Liraglutide Drugs Market Research Report
By Type
Victoza, Saxenda
By Application
Type 2 Diabetes, Obesity
By Companies
Novo Nordisk, Mylan
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Liraglutide Drugs Market Report Segments:
The global Liraglutide Drugs market is segmented on the basis of:
Types
Victoza, Saxenda
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Type 2 Diabetes, Obesity
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novo Nordisk
- Mylan
Highlights of The Liraglutide Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Victoza
- Saxenda
- By Application:
- Type 2 Diabetes
- Obesity
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Liraglutide Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Liraglutide is a type of diabetes medication that helps to control blood sugar levels. It works by helping the body to produce more insulin.
Some of the major companies in the liraglutide drugs market are Novo Nordisk, Mylan.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Liraglutide Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Liraglutide Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Liraglutide Drugs Market - Supply Chain
4.5. Global Liraglutide Drugs Market Forecast
4.5.1. Liraglutide Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Liraglutide Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Liraglutide Drugs Market Absolute $ Opportunity
5. Global Liraglutide Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Liraglutide Drugs Market Size and Volume Forecast by Type
5.3.1. Victoza
5.3.2. Saxenda
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Liraglutide Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Liraglutide Drugs Market Size and Volume Forecast by Application2 Diabetes
6.3.2. Obesity
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Liraglutide Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Liraglutide Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Liraglutide Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Liraglutide Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Liraglutide Drugs Demand Share Forecast, 2019-2026
9. North America Liraglutide Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Liraglutide Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Liraglutide Drugs Market Size and Volume Forecast by Application2 Diabetes
9.4.2. Obesity
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Liraglutide Drugs Market Size and Volume Forecast by Type
9.7.1. Victoza
9.7.2. Saxenda
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Liraglutide Drugs Demand Share Forecast, 2019-2026
10. Latin America Liraglutide Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Liraglutide Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Liraglutide Drugs Market Size and Volume Forecast by Application2 Diabetes
10.4.2. Obesity
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Liraglutide Drugs Market Size and Volume Forecast by Type
10.7.1. Victoza
10.7.2. Saxenda
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Liraglutide Drugs Demand Share Forecast, 2019-2026
11. Europe Liraglutide Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Liraglutide Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Liraglutide Drugs Market Size and Volume Forecast by Application2 Diabetes
11.4.2. Obesity
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Liraglutide Drugs Market Size and Volume Forecast by Type
11.7.1. Victoza
11.7.2. Saxenda
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By ountry
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Liraglutide Drugs Demand Share, 2019-2026
12. Asia Pacific Liraglutide Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Liraglutide Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Liraglutide Drugs Market Size and Volume Forecast by Application2 Diabetes
12.4.2. Obesity
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Liraglutide Drugs Market Size and Volume Forecast by Type
12.7.1. Victoza
12.7.2. Saxenda
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Liraglutide Drugs Demand Share, 2019-2026
13. Middle East & Africa Liraglutide Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Liraglutide Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Liraglutide Drugs Market Size and Volume Forecast by Application2 Diabetes
13.4.2. Obesity
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Liraglutide Drugs Market Size and Volume Forecast by Type
13.7.1. Victoza
13.7.2. Saxenda
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Liraglutide Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Liraglutide Drugs Market: Market Share Analysis
14.2. Liraglutide Drugs Distributors and Customers
14.3. Liraglutide Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novo Nordisk
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Mylan
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. COMPANY3
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. COMPANY4
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
